Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,579 |
Ending reported balance
After 2026-07-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 17,167 · Balance 39,746 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. Row 2 · 2026-07-09 · Sale · Disposed 17,167 · Balance 22,579 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.75 · Expires 2033-06-21 | Direct | 17,167 |
Reported balance
After 2026-07-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-09 · Exercise / conversion · Disposed 17,167 · Balance 17,167 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. F2: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.
F2: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 13, 2026 20:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 17,167 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001470831-26-000709 · wk-form4_1783975290.xml · derivative · entry 3 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,167 Underlying: Common Stock · 17,167 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. F2 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 17,167 | $84.00 | $1,442,028.00 |
DisclosureSEC source: 0001470831-26-000709 · wk-form4_1783975290.xml · nonDerivative · entry 2 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,579 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 17,167 | $16.75 | $287,547.25 |
DisclosureSEC source: 0001470831-26-000709 · wk-form4_1783975290.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,277 | $0.00 Strike: $68.92 | $0.00 |
DisclosureSEC source: 0001470831-26-000630 · wk-form4_1782338749.xml · derivative · entry 2 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000630 · wk-form4_1782338749.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,579 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 64,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001470831-26-000252 · wk-form4_1772834274.xml · derivative · entry 3 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,921 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 64,921 | $64.87 | $4,211,301.92 |
DisclosureSEC source: 0001470831-26-000252 · wk-form4_1772834274.xml · nonDerivative · entry 2 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,589 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $64.255 to $65.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 64,921 | $8.45 | $548,582.45 |
DisclosureSEC source: 0001470831-26-000252 · wk-form4_1772834274.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 20:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 17,167 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0000950170-25-105185 · ownership.xml · derivative · entry 3 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,334 Underlying: Common Stock · 17,167 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. F2 · derivative.exercise_date: The option vests in three annual installments from June 21, 2024 through June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 20:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 17,167 | $49.00 | $841,183.00 |
DisclosureSEC source: 0000950170-25-105185 · ownership.xml · nonDerivative · entry 2 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,589 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 20:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 17,167 | $16.75 | $287,547.25 |
DisclosureSEC source: 0000950170-25-105185 · ownership.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 8,425 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0000950170-25-089673 · ownership.xml · derivative · entry 2 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 6,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089673 · ownership.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,589 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0000950170-25-054883 · ownership.xml · derivative · entry 3 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,921 Underlying: Common Stock · 10,000 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0000950170-25-054883 · ownership.xml · nonDerivative · entry 2 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 10,000 | $8.45 | $84,500.00 |
DisclosureSEC source: 0000950170-25-054883 · ownership.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0000950170-25-050584 · ownership.xml · derivative · entry 3 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,921 Underlying: Common Stock · 30,000 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 30,000 | $34.05 | $1,021,500.00 |
DisclosureSEC source: 0000950170-25-050584 · ownership.xml · nonDerivative · entry 2 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 30,000 | $8.45 | $253,500.00 |
DisclosureSEC source: 0000950170-25-050584 · ownership.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 26,014 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0000950170-24-077443 · ownership.xml · derivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 51,501 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001209191-23-039369 · doc4.xml · derivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 104,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-22-039241 · doc4.xml · derivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 12,000 | $8.39 | $100,680.00 |
DisclosureSEC source: 0000899243-22-011386 · doc4.xml · nonDerivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · price: Represents the weighted average purchase price of the shares purchased from $8.38 to $8.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions as reported in this footnote. Read SEC document |
| August 17, 2021 Filed Aug 26, 2021 21:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 49,869 | $0.00 Strike: $49.54 | $0.00 |
DisclosureSEC source: 0000899243-21-034290 · doc4.xml · derivative · entry 1 Ellis Andrea · CIK 0001877680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,869 Underlying: Common Stock · 49,869 shares Expires 2031-08-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after August 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.